专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US4624925A Hybrid cell line for producing monoclonal antibody to a human early thymocyte antigens, antibody, and methods 失效
标题翻译：用于产生人早期胸腺细胞抗原的单克隆抗体的杂交细胞系，抗体和方法
公开(公告)号：US4624925A
公开(公告)日：1986-11-25
申请号：US432458
申请日：1982-10-04
申请人： Patrick C. Kung , Gideon Goldstein
发明人： Patrick C. Kung , Gideon Goldstein
IPC分类号： A61K38/00 , C07K16/28 , C12P21/08 , G01N33/569 , C12N5/00 , C12N15/00 , C12P21/00
CPC分类号： C07K16/2881 , G01N33/56972 , A61K38/00 , Y10S435/948
摘要： Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
摘要翻译：用于在大约10％的正常人胸腺细胞上发现的用于产生针对抗原的单克隆抗体的杂交细胞系。通过将来自免疫的CAF1小鼠的脾细胞与P3X63Ag8U1骨髓瘤细胞融合来形成杂交体。还公开了单克隆抗体的诊断和治疗用途。

22. 发明授权

US4584284A Bursopoietin 失效
公开(公告)号：US4584284A
公开(公告)日：1986-04-22
申请号：US681971
申请日：1985-01-31
申请人： Tapan Audhya , Daniel J. Kroon , George Heavner , Gideon Goldstein
发明人： Tapan Audhya , Daniel J. Kroon , George Heavner , Gideon Goldstein
IPC分类号： C07K5/08 , A61K38/00 , A61K38/22 , A61P37/00 , C07K1/04 , C07K5/00 , C07K5/09 , A61K37/24 , C08F283/00
CPC分类号： C07K5/0815
摘要： A synthetic peptide which possesses the ability to specifically induce the differentiation of precursor B cells into mature B-cells capable of producing antibody.
摘要翻译：具有特异性诱导前体B细胞分化成能够产生抗体的成熟B细胞的能力的合成肽。

23. 发明授权

US4515894A Hybrid cell line for producing monoclonal antibody to human T cells 失效
标题翻译：用于产生人T细胞单克隆抗体的杂交细胞系
公开(公告)号：US4515894A
公开(公告)日：1985-05-07
申请号：US432453
申请日：1982-10-04
申请人： Patrick C. Kung , Gideon Goldstein
发明人： Patrick C. Kung , Gideon Goldstein
IPC分类号： A61K38/00 , C07K16/28 , C07K16/30 , G01N33/569 , C12N5/00 , C12N15/00
CPC分类号： C07K16/3061 , C07K16/28 , G01N33/56972 , A61K38/00
摘要： Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells. The hybrid is formed by fusing splenocytes from immunized Balb/cJ mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
摘要翻译：用于产生针对所有正常人T细胞上发现的抗原的单克隆抗体的杂交细胞系。通过将来自免疫Balb / cJ小鼠的脾细胞与P3X63Ag8U1骨髓瘤细胞融合形成杂交体。还公开了单克隆抗体的诊断和治疗用途。

24. 发明授权

US4505853A Enzyme-resistant immunomodulatory peptides 失效
标题翻译：耐酶免疫调节肽
公开(公告)号：US4505853A
公开(公告)日：1985-03-19
申请号：US553281
申请日：1983-11-18
申请人： Gideon Goldstein , George Heavner , Daniel Kroon , Tapan Audhya
发明人： Gideon Goldstein , George Heavner , Daniel Kroon , Tapan Audhya
IPC分类号： C07K5/10 , A61K38/00 , A61K38/22 , A61P5/00 , A61P37/00 , C07K1/113 , C07K7/06 , C07K14/52 , C07K14/54 , C07K14/66 , C07C103/52 , A61K37/00
CPC分类号： C07K14/662 , C07K14/66 , A61K38/00 , Y10S930/18
摘要： Peptides which have thymopoeitin-like or splenin-like activity combined with greatly increased resistance to degradation by enzymes. The peptides are useful for treatment of immunoregulatory disorders. Also provided are methods of treating immunoregulatory disorders and compositions used in these methods.
摘要翻译：具有胸腺嘧啶样或脾素样活性的肽与大大提高的酶降解抗性相结合。该肽可用于治疗免疫调节性疾病。还提供了治疗免疫调节障碍的方法和用于这些方法的组合物。

25. 发明授权

US4397842A Peptides having thymopoietin-like activity 失效
标题翻译：具有胸腺生成素样活性的肽
公开(公告)号：US4397842A
公开(公告)日：1983-08-09
申请号：US248759
申请日：1981-03-30
申请人： Gideon Goldstein , George Heavner
发明人： Gideon Goldstein , George Heavner
IPC分类号： A61K38/00 , C07K14/66 , A61K37/00
CPC分类号： C07K14/662 , A61K38/00 , Y10S930/18
摘要： There are disclosed peptides having the following formula:A--X--Z--Y--Bwherein A is ##STR1## X is a suitable neutral, aliphatic or aromatic amino acid residue; e.g., one selected from the group consisting of ALA, 2-Me-ALA, GLY, LEU, ILE, LYS, THR, SER, PHE, MET, D-ALA, D-LEU, D-ILE, D-LYS, D-THR, allo-THR, D-SER, D-PHE, D-MET, and SAR; Z is ##STR2## Y is GLY, SER, THR, LEU, ILE, VAL, OR SAR; B IS TYR-R', D-TYR-R', decarboxy-TYR, or ##STR3## m is 3 or 4; n is 1, 2, or 3; R''' is hydrogen, C.sub.1 -C.sub.7 alkyl, C.sub.6 -C.sub.12 aryl, or C.sub.1 -C.sub.7 alkanoyl; and R and R' are substituents which do not substantially affect the biological activity of the peptides, provided that R-ARG-LYS-ASP-VAL-TYR-R' is excluded. These peptides have the capability of inducing the differentiation of T-lymphocytes but not of complement receptor (CR.sup.+) B-lymphocytes and thus are useful in a number of therapeutic areas. Also provided are derivatives of the peptides, therapeutic compositions, and methods for use of the compositions.
摘要翻译：公开了具有下式的肽：A-X-Z-Y-B其中A是合适的中性，脂族或芳族氨基酸残基; 例如选自ALA，2-Me-ALA，GLY，LEU，ILE，LYS，THR，SER，PHE，MET，D-ALA，D-LEU，D-ILE，D-LYS，D -THR，allo-THR，D-SER，D-PHE，D-MET和SAR; Z是 Y是GLY，SER，THR，LEU，ILE，VAL或OR SAR; B是TYR-R'，D-TYR-R'，脱羧-TYR或者 m是3或4; n为1,2或3; R“是氢，C 1 -C 7烷基，C 6 -C 12芳基或C 1 -C 7烷酰基; 并且R和R'是不排除基本上影响肽的生物学活性的取代基，条件是R-ARG-LYS-ASP-VAL-TYR-R'。这些肽具有诱导T淋巴细胞分化而不是补体受体（CR +）B淋巴细胞分化的能力，因此可用于许多治疗领域。还提供了肽的衍生物，治疗组合物和组合物的使用方法。

26. 发明授权

US4261886A Peptides having thymopoietin-like activity 失效
标题翻译：具有胸腺生成素样活性的肽
公开(公告)号：US4261886A
公开(公告)日：1981-04-14
申请号：US124959
申请日：1980-03-13
申请人： Gideon Goldstein , George Heavner
发明人： Gideon Goldstein , George Heavner
IPC分类号： A61K38/00 , C07K14/66 , C07C103/52
CPC分类号： C07K14/662 , A61K38/00 , Y10S930/18
摘要： There are disclosed peptides having the following formula: 12 A-X-Z-Y-Bwherein A is ##STR1## X is a suitable neutral, aliphatic or aromatic amino acid residue; e.g., one selected from the group consisting of ALA, 2-Me-ALA, GLY, LEU, ILE, LYS, THR, SER, PHE, MET, D-ALA, D-LEU, D-ILE, D-LYS, D-THR, allo-THR, D-SER, D-PHE, D-MET, and SAR; Z is ##STR2## Y is GLY, SER, THR, LEU, ILE, VAl, or SAR; B is TYR-R', D-TYR-R', decarboxy-TYR, or ##STR3## m is 3 or 4; n is 1, 2, or 3; R''' is hydrogen, C.sub.1 -C.sub.7 alkyl, C.sub.6 -C.sub.12 aryl, or C.sub.1 -C.sub.7 alkanoyl; and R and R' are substituents which do not substantially affect the biological activity of the peptides, provided that R-ARG-LYS-ASP-VAL-TYR-R' is excluded. These peptides have the capability of inducing the differentiation of T-lymphocytes but not of complement receptor (CR.sup.+) B-lymphocytes and thus are useful in a number of therapeutic areas. Also provided are derivatives of the peptides, therapeutic compositions, and methods for use of the compositions.
摘要翻译：公开了具有下式的肽：1 2 A-X-Z-Y-B其中A是合适的中性，脂族或芳族氨基酸残基; 例如选自ALA，2-Me-ALA，GLY，LEU，ILE，LYS，THR，SER，PHE，MET，D-ALA，D-LEU，D-ILE，D-LYS，D -THR，allo-THR，D-SER，D-PHE，D-MET和SAR; Z是 Y是GLY，SER，THR，LEU，ILE，VA1或SAR; B是TYR-R'，D-TYR-R'，脱羧-TYR或者 m是3或4; n为1,2或3; R“是氢，C 1 -C 7烷基，C 6 -C 12芳基或C 1 -C 7烷酰基; 并且R和R'是不排除基本上影响肽的生物学活性的取代基，条件是R-ARG-LYS-ASP-VAL-TYR-R'。这些肽具有诱导T淋巴细胞分化而不是补体受体（CR +）B淋巴细胞分化的能力，因此可用于许多治疗领域。还提供了肽的衍生物，治疗组合物和组合物的使用方法。

27. 发明授权

US4258152A Pentapeptide modified resin 失效
标题翻译：五肽改性树脂
公开(公告)号：US4258152A
公开(公告)日：1981-03-24
申请号：US47909
申请日：1979-06-12
申请人： Gideon Goldstein , David H. Schlesinger
发明人： Gideon Goldstein , David H. Schlesinger
IPC分类号： A61K38/00 , C07K5/062 , C08F8/30
CPC分类号： C07K5/06052 , A61K38/00 , Y10S930/28
摘要： There are disclosed polypeptide compositions having the following amino acid sequence as the active site:ARG-LYS-ASP-VAL-TYRThese polypeptides have the capability of inducing the differentiation of T-lymphocytes but not of complement receptor (CR.sup.+) B-lymphocytes and thus are useful in a number of therapeutic areas. Also provided are derivatives of the pentapeptide, novel intermediate polypeptides, methods of manufacture of the peptides, therapeutic compositions, and methods for use of the compositions.
摘要翻译：公开了具有以下氨基酸序列作为活性位点的多肽组合物：ARG-LYS-ASP-VAL-TYR这些多肽具有诱导T淋巴细胞分化而不是补体受体（CR +）B淋巴细胞分化的能力，因此在许多治疗领域中是有用的。还提供了五肽的衍生物，新的中间体多肽，肽的制备方法，治疗组合物和使用该组合物的方法。

28. 发明授权

US4215111A Peptides having ubiquitin-like activity 失效
标题翻译：具有泛素样活性的肽
公开(公告)号：US4215111A
公开(公告)日：1980-07-29
申请号：US020157
申请日：1979-03-14
申请人： Gideon Goldstein , George Heavner
发明人： Gideon Goldstein , George Heavner
IPC分类号： C07K5/04 , A61K38/00 , A61K38/22 , A61P37/00 , C07C235/72 , C07C237/10 , C07C237/22 , C07K5/06 , C07K5/072 , C07K5/083 , C07K5/103 , C07K7/06 , C07K14/66 , A61K37/00 , C07C103/52
CPC分类号： C07K7/06 , C07K14/66 , C07K5/06026 , C07K5/06104 , C07K5/0806 , C07K5/1008 , A61K38/00
摘要： Peptides of the following formula:A-Bwherein A is a member selected from the group consisting of deamino-GLN, GLN, and (SAR).sub.n -GLN; n is an integer from 1 to 4; and B is a member selected from the group consisting of LYS-OH, LYS-NH.sub.2, decarboxy-LYS, ##STR1## LYS-SAR-OH and LYS-SAR-NH.sub.2, have significantly increased ubiquitin-like activity. Also provided are therapeutic compositions and methods for use thereof.
摘要翻译：下式的肽A-B其中A是选自deamino-GLN，GLN和（SAR）n-GLN的成员; n是1至4的整数; 并且B是选自LYS-OH，LYS-NH2，脱羧-LYS，图像LYS-SAR-OH和LYS-SAR-NH2的成员具有显着增加的泛素样活性。还提供了治疗组合物及其使用方法。

29. 发明申请

US20060211108A1 Methods and compositions for impairing multiplication of HIV-1 失效
公开(公告)号：US20060211108A1
公开(公告)日：2006-09-21
申请号：US11353293
申请日：2006-02-13
申请人： Roland Carlsson , Elisabeth Sonesson , Yvonne Stenberg , Leif Strandberg , Gideon Goldstein
发明人： Roland Carlsson , Elisabeth Sonesson , Yvonne Stenberg , Leif Strandberg , Gideon Goldstein
IPC分类号： C12Q1/68 , C12N5/06 , C12N5/16
CPC分类号： C07K16/1072 , C07K2317/92
摘要： A single isolated antibody or antibody fragment thereof binds to multiple variant sequences within an epitope of HIV-1 Tat protein displayed in multiple strains and subtypes of HIV-1. This “pan-epitope” antibody is useful in therapeutic and prophylactic compositions and treatments of HIV-1 infection, regardless of strain. This pan-epitope antibody is useful in assays for the detection of levels of HIV-1 based on a measurement of the amount of Tat protein in a biological sample.

30. 发明授权

US4994554A Probursin 失效
公开(公告)号：US4994554A
公开(公告)日：1991-02-19
申请号：US287462
申请日：1988-12-20
申请人： Tapan Audhya , Gideon Goldstein , George Heavner
发明人： Tapan Audhya , Gideon Goldstein , George Heavner
IPC分类号： G01N33/53 , A61K20060101 , A61K38/00 , A61K38/04 , A61K38/22 , A61K39/395 , A61P1/16 , A61P35/00 , A61P37/00 , C07K20060101 , C07K1/04 , C07K5/08 , C07K7/08 , C07K16/00 , C07K17/08 , C12N15/09 , C12P21/02 , C12R1/91
CPC分类号： C07K7/08 , C07K17/08 , A61K38/00
摘要： A multi-functional mammalian peptide probursin isolated in purified form, produced synthetically or recombinantly can be used therapeutically for treatment of immune disorders and tumor inhibition.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式